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Cutaneous neoplasms including sebaceous tumors, keratoacanthomas, and basal cell carcinomas with sebaceous diﬀerentiation
can be markers of internal malignancy associated with the Muir-Torre Syndrome (MTS). We report a 56-year-old man with
a diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) and ureteral transitional cell carcinoma who subsequently
developed two sebaceous gland neoplasms and several keratoacanthomas, leading to the diagnosis of MTS. Our case highlights the
clinical advantages of immunohistochemistry (IHC) in identifying mutations in the mismatch repair (MMR) genes responsible
for both HNPCC and MTS. The importance of continued clinical suspicion in the dermatological assessment of patients with
sebaceous neoplasms is emphasized.
1.Introduction
Usually diagnosed clinically by the synchronous or metac-
hronous manifestation of a sebaceous neoplasm and visceral
malignancy, most commonly colon cancer, MTS was ﬁrst
described by Muir et al. in 1967 and subsequently by Torre in
1968 [1, 2]. Later, Lynch et al. described several patients with
sebaceous neoplasms, colorectal cancer, and a familial cancer
predisposition and ﬁrst considered MTS as an uncommon
phenotypic variant of HNPCC [3].
Although MTS is a rare, autosomal genodermatosis, the
serious but curable nature of its associated cancers makes
early identiﬁcation paramount. In such, cutaneous neo-
plasms can serve as visible markers of internal malignancy.
The most important of these being sebaceous adenoma,
a relatively rare but benign tumor that presents as yellow
papules or nodules and acts as the most speciﬁc marker of
MTS [4, 5].
2.CaseReport
Ourpatientﬁrstpresentedwithachangeinbowelcaliberand
fatigue. During his interview, a signiﬁcant family history of
cancer was identiﬁed with ﬁve of his ten siblings diagnosed
with a variety of cancers. Speciﬁcally, a sister diagnosed
with colon cancer, a brother diagnosed with kidney cancer,
another brother diagnosed with two colon cancers, a third
brother diagnosed with two colon cancers and skin cancer,
and a fourth brother diagnosed with two colon cancers,
ureter cancer, and skin cancer. Additionally, his father was
diagnosed with colon cancer in his late forties and his
paternal uncle was diagnosed with colon cancer.
With a presentation and family history consistent with
HNPCC, he was initially evaluated with a pelvic-computed
tomography (CT) scan. After visualization of a 3.5 × 5.5cm
mass near the ileocecal valve, an endoscopy-guided biopsy
of the mass was performed. Pathology characterized the
mass as an adenocarcinoma with moderate diﬀerentiation.
A subtotal colectomy followed which conﬁrmed the biopsy
results. No serosal invasion or lymph node involvement
was noted. Following the colectomy, he elected to pursue
research-based testing of the MSH2 and MLH1 genes, the
most common MMR proteins implicated in HNPCC [5].
Theresultsofthisstudyhoweverwereseveralyearsaway,and
in the meantime an increased cancer surveillance program
for the patient and his family members was recommended.2 Dermatology Research and Practice
A year later, he noticed hematuria and a lower abdom-
inal mass. A pelvic CT was ordered which showed right
hydroureteronephrosis, but no external mass. This was fol-
lowed up with an intravenous pyelogram (IVP) and urinary
cytology. The IVP conﬁrmed the hydroureteronephrosis and
cytologicexaminationshowednumeroussmall,atypicalcells
with a high nuclear-cytoplasmic ratio highly suspicious for
malignancy. A low-grade urothelial carcinoma was found
in the right ureter and a right nephroureterectomy was
performed.
Withnoresultsforthcomingintheresearch-basedtesting
of MMR genes and a growing concern for other family
members, he decided to pursue clinical genetic testing. DNA
sequencing for both MSH2 and MLH1 was undertaken.
However, no explainable mutation was discovered and
uncertainty remained.
The patient presented to our dermatology clinic with
concerns of a ﬂesh-colored papule on his left cheek. Surgical
excision and skin biopsy were performed and identiﬁed a
sebaceous adenoma. With the presentation of this sebaceous
neoplasm and his history of visceral malignancy, a new
diagnosis of MTS was made. The following year, a similar
lesion was removed from his chin and biopsy identiﬁed a
keratoacanthoma.
Still without the identity of the causative mutation, he
decided to pursue additional clinical genetic testing utilizing
new Southern blotting technology in the screening of MSH2
and MLH1. This study ﬁnally identiﬁed a deletion of exons
1 through 7 in the MSH2 gene. With an explanation for
his personal cancers and family history, genetic testing was
oﬀered to his extended family.
Since the mutation has been identiﬁed, he has undergone
regular colonoscopies, urinary cytologic analysis, derma-
tologic assessment, and monitoring of carcinoembryonic
antigen (CEA). Colonoscopy and urinary cytology have been
negative and CEA levels have been stable. Subsequent biop-
sies of a variety of skin papules have conﬁrmed a sebaceous
carcinoma and a second keratoacanthoma (Figure 1).
3. Discussion
Although MTS generally presents as a sebaceous neoplasm
plus colorectal adenocarcinoma, a secondary diagnostic
criterion includes multiple keratoacanthomas associated
with visceral neoplasms and a family history of MTS
[5]. The internal cancers implicated include carcinomas of
the genitourinary tract, breast, upper gastrointestinal tract,
larynx, parotid gland, and hematological malignancies. Of
these, tumors of the genitourinary tract (especially ureter
andendometrium)arethemostcommonvisceralneoplasms
seen in MTS after colorectal cancer [4].
Cancer surveillance and early identiﬁcation of these
tumors are important for the implementation of proper
treatment regimens. Because sebaceous tumors can serve as
visible markers of internal malignancy in MTS, a detailed
dermatologic exam is important in these patients. Sebaceous
hyperplasia and solitary keratoacanthoma, relatively com-
mon ﬁndings in the general population, are not consid-
Figure 1: Sebaceous carcinoma of eyelid found during routine
screening of a patient with Muir-Torre Syndrome.
ered markers of MTS, but all other sebaceous neoplasms,
including sebaceous adenoma, sebaceoma, and carcinoma,
are considered highly speciﬁc markers of MTS [5].
Sebaceous adenoma, the most common lesion in MTS,
presents as tan or yellow neoplasms that contain a spectrum
of cells ranging from germinative or basaloid to fully mature
sebocytes.Pleomorphism isexceptional in casesofsebaceous
adenoma [6]. Sebaceomas show a more prominent basaloid
component and are probably more easily confused with
basal cell carcinoma or sebaceous carcinoma. Their basaloid
content is greater than 50% of cellularity by deﬁnition [6].
Sebaceous carcinoma, a malignant tumor, has two distinct
variants: an aggressive form that occurs most frequently on
the eyelids and an extraocular type, whose aggressiveness
is still debated, that occurs most commonly on the head
and neck [7]. In MTS, the extraocular form is the usual
presentation.
Whenever multiple sebaceous tumors are identiﬁed
involving any site or any sebaceous tumor is discovered out-
sideoftheheadandneckregion,especiallyinayoungperson
(<50 years), a thorough work-up for MTS is necessary. The
initial test should be IHC, using antibodies to bind speciﬁc
cellular antigens, to determine the presence or absence of
MMR proteins [5].
MMR genes encode proteins that recognize and remove
improper genomic insertions and deletions, and nucleotide
mismatches that arise during DNA replication and recombi-
nation. Collectively these genes maintain the integrity of the
genome and prevent mutations from accumulating. In MTS,
individualsarebornwithonedefectivecopyofanMMRgene
and acquire a second somatic mutation in the other allele
during their lifetime [5]. Interestingly, it has been shown
that MMR deﬁciency is more likely to be found in benign
sebaceous tumors as compared to sebaceous carcinoma, and
more common in lesions that occur outside the head and
neck [7].
The ﬁrst mutations identiﬁed in MTS involved the MMR
genes MSH2 and MLH1, the same genes known to cause
HNPCC. This insight has led MTS to be considered a
phenotypic variant of HNPCC [3, 8]. Subsequent studiesDermatology Research and Practice 3
have shown that mutations in MSH2 are the most common,
comprising about 90% of MTS cases, and that about 10%
of patients have mutations in MLH1 [8]. Recently however,
individuals have also been identiﬁed with MTS phenotype
but with mutations in MSH6 [9, 10]. This discovery has
added complexity to the MTS genotype, but oﬀers an
additional gene for mutation analysis.
IHC, assessing MSH2, MLH1, and MSH6 activity, and
microsatellite instability (MSI) analysis are currently the two
main screening tests for MTS. Using a combination of these
tests,mostcasesofMTSshouldbeidentiﬁedafterathorough
clinical examination and family history. The recent advances
in IHC and MSI analysis have made the diagnosis of MTS
much simpler.
AlthoughscreeningMMRgenesformutationscandetect
MTS genotypes, the protracted nature of these tests and
the fact that not all causative mutations are known make
these mutation screenings a poor ﬁrst diagnostic choice. The
shortcomings in mutation screenings are highlighted by the
diﬃculty our patient had in identifying a mutation and the
many years before this technique obtained clear results.
Because early diagnosis of MTS is essential for both the
patient and their extended family, we believe that mutational
screenings are not the best initial diagnostic approach.
We agree with recent proposals to use IHC as the initial
screeningtestassayingMSH2,MLH1,andifbothoftheseare
negativeMSH6[5].MSIanalysisandreviewoffamilyhistory
should guide cancer surveillance options for the patient and
extended family after IHC. Mutational analysis should be
considered only as a conﬁrmation step and to screen family
members for necessity of continued cancer surveillance.
It is the responsibility of dermatologists to carry a strong
suspicion when evaluating sebaceous tumors, especially
those with an unusual presentation. The proper tests and
early detection of malignancies will hopefully allow patients
with MTS to reach normal life expectancies.
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